Filing Details

Accession Number:
0001209191-23-056008
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-20 15:28:44
Reporting Period:
2023-11-17
Accepted Time:
2023-11-20 15:28:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1117480 Chimerix Inc CMRX Pharmaceutical Preparations (2834) 330903395
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1267959 A Fred Middleton C/O Chimerix, Inc.
2505 Meridian Parkway, Suite 100
Durham NC 27713
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-11-17 17,295 $0.96 100,000 No 4 P Indirect Fred A. Middleton Separate Property Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect Fred A. Middleton Separate Property Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 207,523 Direct
Common Stock 2,776,093 Indirect See footnote
Common Stock 531,861 Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9500 to $0.9600, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
  2. The securities are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P. and 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares).
  3. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares and the Sanderling VI Shares (as defined herein). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. The securities are held as follows: 498,046 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG and 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares).